Appetite reduction is one visible result, but the mechanism is broader
Postmortem analysis has revealed that insulin resistance (IR) also occur in AD patients brain with significantly decreased expression of the insulin receptor, concomitant with the disease progression (66, 67) and indicated that the defects in insulin signaling are associated with AD pathogenesis (68)
Semaglutide drugs have been available since However, a young or middle-aged person committing to semaglutide or the other diet agonists may be taking them for several, or even many, decades
For complete dosing details, see the tirzepatide dosing guide
Some people notice appetite changes within the first few weeks, while visible weight loss often becomes more noticeable after a few months
39 Therapy with semaglutide resulted in significant weight loss, an increase in 6MWT distance, improvement in quality of life (KCCQ-CSS), and a significant reduction in CRP